DIAGNODE-2 results and meta-analysis with Diamyd[®] to be presented at diabetes conference

Results from the phase IIb trial DIAGNODE-2 with intralymphatic administration of Diamyd[®] as well as the large-scale meta-analysis comprising data from more than 600 individuals treated with Diamyd[®] showing significant treatment effect in individuals carrying the HLA DR3-DQ2 haplotype, will be presented as oral abstracts by Professor Johnny Ludvigsson and PhD Ulf Hannelius, CEO of Diamyd Medical at the Scandinavian Society of the Science in Diabetes (SSSD) on March 11, 2021.The abstracts will be presented during the conference session “Diabetes classification and precision medicine”.